MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-14-2025
Country |
 USA |
IPO year |
1983 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
537 M |
Market Cap[1] |
$ 199 B |
EBITDA (LTM) |
$ 12.4 B |
P/E (LTM) |
28.45 |
P/S (LTM) |
7.64 |
EPS (LTM) |
13.25 |
Amgen is a biopharmaceutical company founded in the USA in 1980. The company is engaged in the development and production of drugs for the treatment of serious diseases such as cancer, rheumatoid arthritis, and osteoporosis.
AMGN is a leading provider of biotechnology products and has over 20,000 employees worldwide. The company has operations in over 100 countries and produces its products in facilities around the world.
The main goal of Amgen is to improve the lives of patients by developing innovative drugs that help fight serious illnesses. The company invests billions of dollars annually in research and development to find new treatment options.
AMGN also advocates for sustainability and environmental protection. The company is committed to reducing its CO2 emissions and making its production processes as environmentally friendly as possible. Amgen is also involved in the community and supports various programs to improve healthcare and education.
Overall, Amgen is an innovative and responsible company dedicated to developing new treatment options for serious illnesses while also striving to protect the environment and support the community.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Akebia Therapeutics
AKBA
|
$ 1.48 | -1.67 % | $ 277 M | Nasdaq Global Market | USA |
 |
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.7 | -0.34 % | $ 5.99 B | Nasdaq Global Market |  Irlanda |
 |
ANI Pharmaceuticals
ANIP
|
$ 79.9 | -0.55 % | $ 1.54 B | Nasdaq Global Market,SPB | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market |  Canada |
 |
Aptorum Group Limited
APM
|
$ 0.88 | 5.24 % | $ 4.8 M | Nasdaq Global Select Market |  China |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Adagene
ADAG
|
$ 2.66 | -0.37 % | $ 150 M | Nasdaq Global Market | China |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.5 | -2.1 % | $ 8.42 B | Nasdaq Capital Market |  Australia |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 110.96 | 0.56 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Cabaletta Bio
CABA
|
$ 2.48 | 1.64 % | $ 2.9 M | Nasdaq Global Select Market | USA |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Compugen Ltd.
CGEN
|
$ 1.75 | 2.05 % | $ 157 M | Nasdaq Global Market,SPB |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Ascendis Pharma A/S
ASND
|
$ 220.07 | -0.88 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 41.12 | -0.46 % | $ 4.24 B | Nasdaq Capital Market,SPB | USA |
 |
Burford Capital Limited
BUR
|
$ 9.23 | 2.9 % | $ 1.44 B | NYSE | Britain |
 |
Aridis Pharmaceuticals
ARDS
|
- | 17.91 % | $ 11.1 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
$ 24.29 | -0.67 % | $ 2.88 B | Nasdaq Capital Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 49.94 | 0.48 % | $ 4.21 B | Nasdaq Global Market,SPB |  Schweiz |
|
Champions Oncology
CSBR
|
$ 6.54 | -0.15 % | $ 89.3 M | Nasdaq Capital Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 4.45 | 5.33 % | $ 9.68 B | NYSE American | Israel |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.46 | - | $ 373 M | Nasdaq Global Select Market | Britain |
 |
Amneal Pharmaceuticals
AMRX
|
$ 14.48 | -0.28 % | $ 4.47 B | NYSE | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.